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ABSTRACT
Pompe disease (PD) is a rare, inherited autosomal recessive metabolic disorder caused by the deficiency of the lysosomal acid 
alpha-glucosidase (GAA) enzyme described in 1932 by the Dutch pathologist Joannes Cassianus Pompe. The prevalence 
of PD ranges from 1:40,000 to 1:300,000 births and depends on geographic and ethnic factors. Clinical manifestations 
may vary from a rapidly progressive disabling disease with cardiomegaly, hepatomegaly, weakness, generalized hypotonia, 
and death within the first year of life, to a mild presentation characterized by slowly progressive myopathy predominantly 
involving the skeletal muscles. The laboratory diagnostic gold standard is represented by the determination of the alpha-
glucosidase activity. However, the muscle histology may also yield the diagnosis by evaluating the tissular glycogen 
accumulation. Until recently, supportive measures constituted the unique available therapy. Currently, the administration 
of the recombinant GAA is being used with promising results. The authors present the case of a 5-month-old boy, 
previously diagnosed with hypertrophic cardiomyopathy since the age of 2 months, who presented acute heart failure 
accompanied by biventricular dilation followed by refractory shock and death. The autopsy findings confirmed the 
glycogen-accumulation disease. 
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CASE REPORT
A 5-month-old boy, previously diagnosed with 
non-obstructive hypertrophic cardiomyopathy was 
brought to the emergency facility with a 3-week history 
of progressive hypoactivity, loss of appetite, decreased 
diuresis, and vomiting. Fever was absent.
The diagnosis of hypertrophic cardiomyopathy 
had been made at the age of 2 months. From 
that time, he began outpatient follow-up at a 
tertiary hospital, and was prescribed propranolol. 
An echodopplercardiogram performed 1 month ago 
showed marked biventricular wall thickening and right 
ventricle diastolic dysfunction, but the left ventricle 
systolic and diastolic functions were preserved.
On the day after admission a new echodopplercar-
diogram was undertaken, which showed left ventricle 
hypertrophy and dilation with systolic dysfunction 
(left ventricular ejection fraction of 38% [Teichholz]), 
marked mitral insufficiency due to valvular ring dilation, 
and a non-restrictive pericardial effusion. His clinical 
status worsened, with pallor, peripheral hypoperfusion 
(which was non-responsive to volume resuscitation), 
liver enlargement, and cardiac arrest, which did not 
respond to routine measures of advanced life support.
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AUTOPSY FINDINGS
The ectoscopy of a male child corpse weighing 
7.3 kg (between the 15th and 50th percentile for the 
age)1 and 70 cm of height (97th percentile for the age),1 
was unremarkable.
The brain weighed 742 g (reference value [RV]: 
413 g) presenting no gross abnormalities. At microscopy, 
the neurons exhibited periodic acid-Schiff (PAS)-positive 
material filling vacuoles predominantly in the bulb and 
pons (Figure 1).
The heart weighed 168 g (over the 95th percentile 
for the age)1 with dilated chambers and a thickened 
interventricular septum that measured 1.2 cm, and 
a ventricular wall width of 0.7 cm and 1.2 cm in the 
right and left ventricles, respectively. The microscopic 
examination revealed a vacuolar PAS-negative myopathy 
(Figure 2).
The right lung weighed 48 g and the left 78 g 
(25th percentile for the age)1 showing lower lobes 
congestion mainly in the left side. The microscopy 
evidenced edema, congestion, and alveolar hemorrhage 
with hemosiderin-loaded macrophages in the alveolar 
space.
The esophagus was normal, grossly, but presented 
mild chronic esophagitis with focal ulceration at 
microscopy.
The liver weighed 210 g (between the 5th and 
25th percentile for the age),1 and presented a smooth 
surface with purplish dots, which were also noticed 
at the parenchymal cut surface of the subcapsular 
region. The microscopy evidenced vacuolization 
of hepatocytes (Figure 3A), filled by PAS-positive 
material. The right and left kidneys weighed 34 g and 
36 g, respectively, (between 75th and 95th percentile 
for the age)1 with a nut-brown color and a smooth 
Figure 1. Photomicrography of the brain. A - Medulla oblongata with vacuoles on neurons (H&E, 200X); B - Medulla 
oblongata with intraneuronal vacuolar neuropathy (PAS, 200X); C - Pons showing neurons with vacuolated cytoplasm 
(H&E, 100X); D - Pons with PAS-positive material filling those vacuoles (PAS, 200X).
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surface. The microscopic examination showed medullar 
congestion and thickening of the arterioles, besides 
the presence of PAS-positive material deposition in the 
mesangium and Bowman’s space (Figure 3B).
The bone marrow was moist and reddish, and 
showed normal cellularity and preserved hematopoiesis. 
PAS-posit ive material was present within the 
hematopoietic cells (Figure 4A and 4B).
Figure 2. Photomicrography of the myocardium. A (H&E, 100X) and B (PAS, 100X) showing diffuse vacuolar PAS 
negative myopathy; C (H&E, 400X) and D (PAS, 400X) myocardiocytes with cytoplasm vacuolization, PAS negative 
in detail.
Figure 3. A - Photomicrography of the liver. Diffuse hepatocyte vacuolization (H&E, 400X); B - Photomicrography 
of the kidney. – PAS-positive material deposition in the mesangium and in Bowman’s space (PAS, 400X).
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The skeletal muscle was grossly normal, but 
at microscopy, an accumulation of a light material 
between the fibers was found, as well as vacuolization 
of the cytoplasm (vacuolar myopathy) with PAS-positive 
material (Figure 4C and 4D). The same pattern of 
vacuolar myopathy (PAS positive) was also present in 
the bladder smooth muscle along with the diaphragm 
and the tongue.
DISCUSSION
Glycogenosis type II, also known as Pompe disease 
(PD), or acid maltase deficiency, is a rare autosomal 
recessive inherited disease caused by the deficiency 
of the acid alpha-glucosidase (GAA) (also known 
as lysosomal acid maltase), described by the Dutch 
pathologist Joannes Cassianus Pompe, in 1932.2 
This enzyme takes part in the degradation process 
of glycogen into glucose within the muscle fibers. 
Mutations in the GAA gene induce varied degrees of 
enzyme deficiency, resulting in the accumulation of 
glycogen within the lysosomes.3 The prevalence of PD 
ranges between 1:40,000 and 1:300,000 births and is 
dependent on ethnic and geographical factors.4
Phenotypes of GAA deficiency comprise three 
forms of the disorder; namely the infantile, the 
childhood, and the late-onset or adult myopathy 
forms.5 The infantile form is more frequent among 
the Afro-descendant and Chinese population, while 
the adult form is more frequent among the Dutch. 
The neonatal screening program for lysosomal storage 
disease showed a higher frequency than expected in 
Taiwan and Austria.4,6
The classic or infantile PD is the more aggressive 
and severe form, which is characterized by rapidly 
progressive behavior with marked cardiomegaly, 
hepatomegaly, weakness, hypotonia, and death due to 
respiratory failure in the first year of life,6 as observed 
Figure 4. A and B - Photomicrography of the bone marrow. A - Intracytoplasmatic vacuoles on histiocytes (H&E, 400X); 
B - PAS-positive material inside histiocytes vacuoles (PAS 400X); C and D - Photomicrography of the skeletal muscle. 
C - Vacuolar myopathy (H&E, 100X); D - Skeletal muscle with PAS-positive material deposition (PAS, 400X).
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in the patient reported herein. The non-classic 
or childhood form presents less severe cardiac 
involvement, the spectrum of which ranges from 
unaffected to moderate cardiac hypertrophy and 
cardiac dysfunction.6 The adult form is characterized 
by slowly progressive myopathy predominantly 
involving the skeletal muscles, which starts from the 
second until the sixth decades of life.6 The late-onset 
form may affect respiratory muscles, which will 
be responsible for significant morbidity.7 In 2005, 
Hagemans et al.8 published a study comprising 
54 patients with the late-onset form of the disease 
showing (with substantial heterogeneity) the mean 
age of initial symptoms at 28.1 years. However, 85% 
of the patients had presented mild muscular symptoms 
during their infancy. In this study, the speed of disease 
progression was also heterogeneous.
PD physiopathology is based upon the glycogen 
accumulation secondary to the GAA deficiency, which 
causes enlargement and rupture of the lysosomes 
membrane with leakage of its contents into the 
sarcoplasm directly displacing and disrupting the 
contractile apparatus. The lysosomal enlargement 
triggers autophagic vacuoles that act in the cytoplasm 
and hamper the contractile function of the eventually 
preserved fibers due to their size, which may reach 
up to half of the fiber diameter.9 In this setting, three 
autophagic mechanisms have been described, namely: 
(i) microautophagy – when cytoplasmic components 
are engulfed by the lysosomes; (ii) chaperone-mediated 
autophagy – when cytosolic hydrosoluble pentapeptide 
proteins are recognized by molecular chaperones, 
which transport them into the lysosome through a 
receptor (LAMP-2A); and (iii) macroautophagy – the 
most relevant and physiologic mechanism in PD – when 
proteins or proteic agregates and organels are 
degraded.7,10 Macroautophagy involves the formation 
of a double-membrane vesicle that engulfs cytoplasmic 
constituents and damaged organelles, which fuses 
with lysosome and degrades its contents. In the 
context of the lack of intracellular nutrients in PD, 
macroautophagy provides energy and amino acids.2,4
The recombinant GAA is an enzyme that acts in 
the three autophagic pathways.4,7,10
Diagnosis of infantile-onset PD may be suspected 
in the presence of a massive cardiomegaly on the 
chest x-ray accompanied by a short PR interval 
and tall QRS complexes on the electrocardiogram. 
The echodopplercardiogram will show hypertrophic 
cardiomyopathy with or without outflow tract 
obstruction that becomes dilated and severely 
dysfunctional in the late stages. Creatinine kinase (CK) 
determination is altered almost totally in the early forms 
of the disease, as are aspartate transaminase, alanine 
transaminase, or lactic dehydrogenase. However, late 
onset form may present CK within the normal limits.6
The current gold-standard diagnostic exam for the 
confirmation of type II glycogenosis is the determination 
of GAA activity (markedly reduced) in cultured skin 
fibroblasts or leukocytes (specifically lymphoid line 
cells or mononuclear cells). New methods have been 
developed to determine GAA activity in dried blood 
spot assay.2,11 Although sensible, but less specific, the 
determination of a glucose tetrasaccharide in the urine, 
the Glc4, can also be used for the diagnosis of PD, 
but may be altered in other glycogen storage diseases 
too, requiring clinical correlation for the precise 
interpretation.12 The combination of the increased 
urinary Glc4 determination with the serum activity of 
GAA achieves approximately 100% of sensitivity for 
the diagnosis of the infantile form of PD, while normal 
values for both determinations virtually rule out this 
diagnosis avoiding further invasive investigation in the 
form of a muscle biopsy or fibroblast cultures.6 The use 
of a non-specific fixative for glycogen preservation can 
wash-out the glycogen deposits. Alcoholic fixatives are 
superior on the conservation of such deposits, and the 
use of these fixatives can demonstrate the glycogen 
deposits in optical and electron microscopy. However, 
even when the aqueous based fixatives are used, such 
as formalin, the presence of vacuolar myopathy can 
be detected on histological examination
Although the determination of the GAA activity 
is the first choice examination for the PD diagnostic 
work-up, molecular analysis of the GAA gene 
mutations may be useful in suspected cases or in the 
adult form when residual GAA activity may be present. 
More than 100 mutations and several variations in 
the GAA encoding gene were identified and are 
cataloged in the Erasmus University Medical Center 
(Rotterdam/Holland). Among the recurrent infantile 
form, the single base pair deletion ∆525T corresponds 
to 34% of cases in Holland13 and 9% in the USA.14 
The exon 18 deletion corresponds to 25% of cases 
in Holland and Canada, and 5% in the USA.6,13,14 
The leaky IVS1(–13T>G) splice-site mutation accounts 
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for 50% of the late-onset forms.14 Some populations 
exhibit specific mutations, such as the R854X mutation, 
which is found in many African and African-American 
cases; the D645E is found among Chinese infantile 
form cases; the 2741AG->CAGG insertion is found in 
Turkish cases; and the G925A mutation in European 
cases.6
The muscle biopsy plays an important role in 
the work-up of PD mainly in the absence of familial 
history.2 Although invasive, the histopathology enables 
a faster diagnosis showing the presence of rounded 
vacuoles that are irregular in shape and size and filled 
by PAS-positive material that corresponds to glycogen 
accumulation within the lysosomes; in advanced 
cases, this is also dispersed in the cytosol. Lipofuscin 
accumulation and lipid droplets may also be observed. 
The vacuoles may also stain intensively to acid 
phosphatase confirming the vacuoles are secondary 
lysosomes.2,15 Ultrastructurally Z-line streaming and 
thickening, as well as non-specific mitochondrial 
alterations, may be observed in infantile and juvenile 
cases.15 In the adult form, due to the heterogeneity 
of glycogen accumulation in different muscle groups 
or different muscle fibers in the same sample, the site 
of the biopsy may render misdiagnosis. The vacuole 
frequency is up to 100% in the infantile form, 75% in 
the childhood form, and 10–50% in the adult form.15 
The amount of glycogen storage may be 10-fold 
greater in the infantile form when compared with 
normal muscular fibers; whereas in the late-onset 
disease this increment is smaller.6
The histology of the patient presented herein 
permitted confirmation of the diagnosis by showing the 
vacuolization of the cytoplasm with the accumulation 
of PAS material between the muscle fibers, which 
is also found in the bladder smooth muscle, the 
diaphragm, and the tongue. Similar findings, in this 
case, comprised the involvement of bone marrow, 
kidneys, and liver.
The PAS-negative vacuolar cardiomyopathy 
observed in our patient may be a consequence of artifact 
fixation and wash-out during histological preparation. 
However, the gross finding of the heart was indeed 
consistent with PD since the cardiac response to 
glycogen accumulation resulted in hypertrophy or 
hypertrophic and dilated cardiomyopathy.
The differential diagnosis of PD comprises other 
glycogen storage diseases, metabolic myopathy and 
muscular dystrophy, which may exhibit similarities 
concerning many of the clinical features as shown in 
the laboratory work-up.6,8
Until recently, specific treatment for PD was 
not available, and supportive measures were the 
only reasonable therapy. Limited benefits were 
achieved with the intake of high protein diets, 
alanine, and branched-chain amino acids. Enhancing 
glycogen-breakdown agents like epinephrine and 
glucagon were tested without benefits.6 Currently, 
studies are being undertaken regarding replacement of 
the lacking enzyme. Clinical trials involving recombinant 
human GAA replacement in infantile-form patients 
show increased survival, reduction of the cardiomegaly, 
and improvement of cardiac and skeletal muscle 
function. Cardiac function improvement seems to 
not depend on the precocity of therapy; however, the 
skeletal muscle response shows better results when 
the treatment is started before marked muscular 
damage and eventhough the response to therapy is 
less encouraging. The type of muscle fiber, the stage 
of the disease at the initial therapeutic regimen, the 
genotype, and the immune response against the 
recombinant enzyme may play an important roles in 
the therapeutic success.
Larger clinical trials are being held to evaluate 
long-term benefits and enzyme replacement dosage. 
Survival is becoming a reality with such therapy and 
the outcome of the disease in the treated patients is 
fundamental.4,6 Type II glycogenosis genetic therapy is 
also being developed. Studies show that the expression 
of the GAA gene in the muscle cells or the secretion 
of the enzyme by the liver produces a decrement of 
the disease in rats. Pharmacological chaperones that 
restore the affected protein morphology and biological 
function may be a future therapy.4
Unfortunately, the patient of this report was 
not diagnosed early and properly. It is likely that the 
outcome could have been more promising if the 
recombinant enzyme replacement, which is currently 
available, had been used. Besides clinical awareness, 
all efforts should be focused for an early and precise 
diagnosis; it is only this way that these patients may 
experience an extended lifespan.
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